Responsive BP reduction within minutes in the preoperative clinical setting1,2

92.5% of patients on CLEVIPREX achieved treatment success*2

The primary endpoint was the incidence of treatment failure, defined as the inability to decrease SBP by ≥15% from baseline or the discontinuation of study treatment for any reason within the 30-minute period after study drug initiation.2

Rotate icon
Success rate (%) (n=53) (n=52) PLACEBO 0 20 40 60 80 100 92.5 17.3 Treatment success rate*2 P<0.0001 CLEVIPREX

*Treatment success was defined as a reduction of SBP of ≥15% from baseline within the 30-minute period from study drug initiation.

Rotate icon
Mean change from baseline in SBP (mmHg) CLEVIPREX PLACEBO –50 –40 –30 –20 –10 0 0 5 10 15 20 25 30 Time (minutes) Mean change in SBP (mmHg)during 30-minute infusion1

Target SBP reduction (≥15% from baseline) achieved with a median time of 6 minutes2